Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs DraftKings Inc (DKNG) Price & Performance

Alnylam Pharmaceuticals, Inc.Trade
DraftKings IncTrade

Price performance (Past 24H)

Key statistics

Alnylam Pharmaceuticals, Inc. vs DraftKings Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $223.26 (market cap $29.60B), while DraftKings Inc trades at $25.69 (market cap $12.58B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 2.4× DraftKings Inc's market cap, and DraftKings Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.

ALNYDKNG
Market Cap
$29.60B$12.58B
Sector
HealthConsumer Cyclical
52-Week High
$491.22$48.23
52-Week Low
$205.48$20.72
Enterprise Value
$27.56B$13.51B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Alnylam Pharmaceuticals, Inc.

ALNY trades at $222.54, up 2.56% today, amid a bearish technical signal with support at $218 and resistance at $223. The company reported strong revenue growth to $3.71B in 2025 and turned profitable with net income of $313.75M, though recent Q2 2026 earnings missed estimates. Analyst consensus remains bullish with a $370.07 price target, but multiple law firms are investigating potential securities fraud, creating near-term uncertainty.

The outlook is mixed: robust fundamentals and analyst support suggest long-term upside, but legal risks and recent earnings volatility pose significant headwinds. Investors face tension between strong profitability metrics and heightened sentiment risks from ongoing investigations.

DraftKings Inc

DraftKings (DKNG) trades at $25.65, up 5.69% on the day, with a bullish technical signal and strong analyst support. The company reported mixed Q2 2026 results, missing earnings estimates but showing robust prediction market growth. Revenue reached $6.05B in 2025, with positive net income of $3.71M, marking a significant turnaround from prior losses. Cash flow from operations improved to $662.86M, though net cash flow turned negative in 2026 projections.

The outlook is cautiously optimistic, driven by prediction market expansion and cost management, but risks include intense competition and promotional pressures. With a consensus price target of $34.00 and 73% buy ratings, upside potential exists if execution continues. Investors should weigh growth prospects against valuation premiums and earnings volatility.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.

Read more on ALNY

About DraftKings Inc

DraftKings Inc is a digital sports entertainment and gaming company. The company provides users with daily fantasy sports (DFS), sports betting, and iGaming opportunities and is also involved in the design & development of sports betting and casino gaming platform software for online and retail sportsbook and casino gaming products. It operates in two segments: Business-to-consumer(B2C) and Business-to-Business(B2B), of which the vast majority of its revenue comes from the B2C segment. Geographically, it derives most of its revenue from the United States.

Read more on DKNG